Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
Clinical trial NCT06942156 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06942156
- Sponsor
- Chong Kun Dang Pharmaceutical
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-14
- Primary completion
- 2030-12-01
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.